Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) reported a strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, advancing its U.S. expansion for minimally invasive microwave ablation (MWA) technology. The company highlighted clinical applications at a thermal ablation workshop and engaged Key Opinion Leaders and emerging physicians.

Leadership said the engagements aim to accelerate adoption of precision, non-surgical interventions to expand patient access and elevate standards of care across the United States.

News Market Reaction – BDMD

-7.42%

10 alerts

-7.42% News Effect

+13.8% Peak Tracked

-11.8% Trough Tracked

-$10M Valuation Impact

$119M Market Cap

0.1x Rel. Volume

On the day this news was published, BDMD declined 7.42%, reflecting a notable negative market reaction. Argus tracked a peak move of +13.8% during that session. Argus tracked a trough of -11.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $119M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.88 Vol: Volume 1,134,276 is 0.21x...

low vol

$2.88 Last Close

Volume Volume 1,134,276 is 0.21x the 20-day average of 5,408,874, indicating subdued trading ahead of this news. low

Technical Shares at $3.13 are trading above the 200-day MA of $2.30, but remain 56.9% below the 52-week high.

Peers on Argus

BDMD was down 0.32% pre-news while key peers showed mixed moves: ICAD up 3.48%, ...

1 Up 1 Down

BDMD was down 0.32% pre-news while key peers showed mixed moves: ICAD up 3.48%, APYX down 1.58%, ICCM down 5.69%, NSPR up 0.61%, XTNT down 6.27%. Momentum scanner names (PROF up 7.34%, LUNG down 5.40%) also diverged, pointing to stock-specific rather than sector-wide drivers.

Common Catalyst Same-day peer news from ICCM and BDMD both highlight minimally invasive ablation-based therapies within medical devices.

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	AI software update	Positive	+38.1%	Announced AI-driven surgical software and began multi-region regulatory registration.
Mar 02	Conference expansion push	Positive	-5.7%	Highlighted U.S. expansion strategy via NASOIE 2026 clinician engagement on MWA.
Feb 25	U.S. thyroid expansion	Positive	+29.0%	Reported expanded U.S. clinical use of MWA for benign thyroid conditions.
Feb 19	Conference showcase plan	Positive	+12.3%	Planned MWA thyroid solution showcases at three U.S. clinical conferences.
Feb 11	Hospital launch	Positive	-7.6%	Announced commercial launch and first benign thyroid ablation at a U.S. hospital.

Pattern Detected

Recent U.S. expansion and technology updates have generally seen positive reactions, but with notable selloffs on some otherwise constructive commercialization milestones.

Recent Company History

Over the past month, BDMD has issued a series of U.S. expansion and technology updates. On Feb 11, a commercial launch at Bakersfield Memorial Hospital saw a -7.62% next-day move. Subsequent U.S. thyroid expansion news on Feb 25 and conference plans on Feb 19 coincided with gains of 28.96% and 12.32%. The Mar 4 AI-driven surgical software announcement triggered a 38.15% move, while NASOIE 2026 participation on Mar 2 led to a -5.7% decline, underscoring uneven reactions to expansion news.

Market Pulse Summary

The stock moved -7.4% in the session following this news. A negative reaction despite expansion-focu...

Analysis

The stock moved -7.4% in the session following this news. A negative reaction despite expansion-focused news fits prior divergence episodes where constructive commercialization milestones were followed by moves of -5.7% and -7.62%. This context suggests that optimism around conferences and clinical showcases has not always translated into durable market confidence. Regulatory disclosures about sizeable registered resale shares and broader China-related risks in recent filings may also influence downside pressure.

Key Terms

microwave ablation, thermal ablation

2 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

thermal ablation medical

"MWA platforms garnered significant interest during the event's thermal ablation workshop"

Thermal ablation is a medical procedure that destroys unwanted tissue—most often tumors—by applying controlled heat through small needles or probes, rather than removing tissue with large incisions. For investors it signals demand for specialized devices, treatment centers and reimbursement changes because it offers a less invasive, often faster alternative to surgery—think of using a hot soldering iron to melt away a tiny damaged spot instead of tearing out a whole panel.

AI-generated analysis. Not financial advice.

NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options.

Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation workshop and at the Company's dedicated exhibit. Leadership facilitated targeted discussions with established Key Opinion Leaders (KOLs) and emerging physicians, exchanging critical insights on the clinical applications of MWA technology. Through these interactions, the Company showcased how integrating precision, non-surgical interventions into modern treatment paradigms can elevate the standard of patient care.

"Our robust presence at NASIT directly advances our mission to elevate the standard of care across the United States," stated Mark Saxton, U.S. CEO of Baird Medical. "By connecting with established pioneers and new specialists at the forefront of thermal ablation, we are accelerating the adoption of precision therapies and empowering providers to deliver superior, minimally invasive outcomes."

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-in-interventional-thyroidology-at-nasit-2026-302707873.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce at NASIT 2026 on March 9, 2026?

Baird Medical showcased its microwave ablation (MWA) platforms and engaged clinicians at NASIT 2026. According to the company, leadership held targeted discussions with KOLs and emerging physicians to highlight clinical applications and promote wider U.S. adoption.

How will Baird Medical's NASIT 2026 activities affect patient access to MWA (BDMD)?

The NASIT engagement aims to expand patient access to minimally invasive MWA treatments in the U.S. According to the company, showcasing clinical use cases and training clinicians is intended to accelerate adoption and integrate non-surgical options into treatment pathways.

Which clinical audiences did BDMD target at the NASIT 2026 thermal ablation workshop?

Baird Medical targeted established Key Opinion Leaders and emerging physicians during the workshop. According to the company, these interactions focused on exchanging clinical insights to support adoption of precision, minimally invasive thermal ablation techniques.

What does Baird Medical (BDMD) claim about its MWA technology following NASIT 2026?

The company presented its MWA platforms as precision, non-surgical interventions that can elevate standard of care. According to the company, demonstrable clinical applications and peer engagement at NASIT reinforce its U.S. expansion strategy.

Will Baird Medical (BDMD) use NASIT engagements to accelerate U.S. expansion of MWA?

Yes, the company frames NASIT participation as a step to accelerate U.S. expansion of MWA technology. According to the company, targeted discussions and demonstrations with clinicians are intended to drive broader clinical adoption and patient access.